The study was carried out between April 3 and June 19 to assess potential bottlenecks in manufacturing the vaccine and the global capacity available to produce them, CEPI said in a statement on Wednesday.
‘Globally, companies can produce 2-4 billion Covid vaccine doses by 2021 end’
